Singhal Vikas, Dhampalwar Swapnil, Saigal Sanjiv, Choudhary Narendra, Saraf Neeraj, Chaudhary Adarsh, Soin Arvinder
Department of GI Surgery, GI Oncology & Bariatric Surgery, Medanta- The Medicity, Gurugram, India.
Institute of Liver Transplantation & Regenerative Medicine, Medanta- The Medicity, Gurugram, India.
J Clin Exp Hepatol. 2021 Jan-Feb;11(1):144-148. doi: 10.1016/j.jceh.2020.05.008. Epub 2020 Jun 6.
Liver transplant recipients may develop weight gain, metabolic syndrome, and subsequent nonalcoholic steatohepatitis of the transplanted liver which impairs graft function. Bariatric surgery is an effective modality for management of morbid obesity and metabolic syndrome. Our aim is to review the role of bariatric surgery in such high-risk posttransplant patients not responding to medical management and highlight the important considerations.
We review the management of two cases with posttransplant metabolic syndrome not responding to medical management and discuss the literature available on bariatric surgery in organ transplant patients.
The first patient was a 51-year-old man who underwent living donor liver transplantation 3 years prior, and follow-up ultrasound and fibroscan was suggestive of steatohepatitis of the graft. After liver transplantation, he had gained 30 Kg weight and was on oral hypoglycemic agents with HbA1c of 8%. The second patient was a 65-year-old man, who gained 30 Kg weight with risk of graft impairment 4 years after of combined liver and kidney transplant. Both patients were evaluated thoroughly preoperatively for risk stratification including an upper gastro-intestinal (GI) endoscopy. The immunosuppression was reduced and monitored closely perioperatively. Both patients underwent laparoscopic sleeve gastrectomy (LSG) and were discharged on postoperative day 3. The first patient was evaluated a year after surgery with body mass index (BMI) reduction from 42 to 34 and second at 2 months with BMI reduction from 38 to 33; both patients were free of diabetes and had stable graft functions.
Bariatric surgery in liver transplant recipients has significant challenges with higher complication rates as patients are on immunosuppression which often impairs wound healing. LSG is safe and effective in such patients which often requires good coordination between the bariatric team and liver transplant team.
肝移植受者可能会出现体重增加、代谢综合征以及随后移植肝的非酒精性脂肪性肝炎,这会损害移植肝功能。减重手术是治疗病态肥胖和代谢综合征的有效方式。我们的目的是回顾减重手术在这类对药物治疗无反应的高风险移植后患者中的作用,并强调重要的注意事项。
我们回顾了两例对药物治疗无反应的移植后代谢综合征患者的治疗情况,并讨论了器官移植患者减重手术的现有文献。
首例患者为一名51岁男性,3年前接受活体供肝移植,随访超声和肝脏硬度值测定提示移植肝脂肪性肝炎。肝移植后,他体重增加了30千克,正在服用口服降糖药,糖化血红蛋白为8%。第二例患者为一名65岁男性,在肝肾联合移植4年后体重增加了30千克,有移植肝受损风险。两名患者术前均进行了全面评估以进行风险分层,包括上消化道内镜检查。围手术期减少免疫抑制并密切监测。两名患者均接受了腹腔镜袖状胃切除术(LSG),术后第3天出院。首例患者术后一年接受评估,体重指数(BMI)从42降至34,第二例患者术后2个月接受评估时BMI从38降至33;两名患者均摆脱了糖尿病,移植肝功能稳定。
肝移植受者进行减重手术面临重大挑战,并发症发生率较高,因为患者正在接受免疫抑制治疗,这往往会损害伤口愈合。LSG在这类患者中是安全有效的,这通常需要减重团队和肝移植团队之间的良好协作。